Wuxi Griffin Opens a New Aseptic Fill Finish Facility

Jan 04, 2018
By BioPharm International Editors

On Jan. 4, 2018, contract manufacturer Wuxi Griffin announced the completion of a new 27,450-ft2 aseptic fill/finish facility in Wuxi, China. The facility is equipped with three filling suits and uses restricted access barrier systems and isolator production technology.

According to the company, the facility is compliant with GMP standards and offers manufacturing services for monoclonal antibodies, vaccines, recombinant proteins, biosimilars, and small-molecule drugs. Small- and medium-sized batch clinical trial manufacturing and commercial manufacturing are also available.

“There are few domestic Chinese contract manufacturers that are international players. There is a gap between the Chinese manufacturers capabilities and the regulatory requirements from the West. Wuxi Griffin is filling this gap by offering western GMP compliance from China,” said Torgny Lundgren, CEO of Wuxi Griffin, in a company press release.

Source: Wuxi Griffin

lorem ipsum